VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on April 23, 2026. The Company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "VNRX". The filing addresses the status of the Company's compliance with NYSE American continued listing standards regarding stockholders' equity.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it confirms the Company has reported losses from continuing operations and/or net losses in its recent fiscal years, triggering the equity compliance requirements under Section 1003(a) of the NYSE American Company Guide.
Material Changes and Listing Status
- Compliance Notice: The Company previously received a notice of non-compliance with NYSE American listing standards due to insufficient stockholders' equity relative to its loss history.
- Plan Acceptance: On April 22, 2026, the NYSE American accepted the Company's plan to regain compliance.
- Compliance Deadline: The Company has been granted a "Plan Period" until August 6, 2027, to meet the required equity thresholds.
- Trading Status: The Company's shares will continue to be listed and traded on the NYSE American during the Plan Period, subject to periodic reviews of progress.
Outlook, Risks, and Contingencies
Management intends to take all reasonable measures to regain compliance by the August 6, 2027 deadline. The filing highlights significant risks, including the possibility that the Company may fail to regain compliance or make sufficient progress, which could lead to the initiation of delisting proceedings by the NYSE American. The Company cautions that failure to comply could materially and adversely affect its results of operations and stock price.
Key Facts for Investor Verification
- Verify the specific stockholders' equity threshold the Company must meet by August 6, 2027, based on its loss history (ranging from $2.0 million to $6.0 million per the Company Guide).
- Review the Company's most recent Form 10-Q or 10-K to assess current equity levels and the feasibility of the compliance plan.
- Monitor future periodic reviews by the NYSE American regarding the Company's progress during the Plan Period.
- Confirm that no immediate delisting action has been taken as of the filing date.